As China plans for demographic crisis, some sectors see opportunity (opens original article in a new tab)

As China's population ages, Goldman Sachs predicts the pharmaceutical and biotech sectors will benefit the most, while carmakers and tech hardware manufacturers may face challenges. The report highlights specific companies with strong demographic-driven demand outlook.

• China's aging population may boost pharmaceutical and biotech sectors
• Carmakers and tech hardware manufacturers face challenges due to demographic shifts
• Goldman Sachs highlights specific companies with strong demographic-driven demand outlook